Pharmacokinetics of famotidine in patients with cirrhosis and ascites.
The pharmacokinetics of famotidine has been investigated in ascitic cirrhotic patients. 10 decompensated cirrhotic patients were studied (9m, 1f), who had normal renal function, and six healthy control subjects (4m, 2f), matched for age, sex and weight. Each subject received on two occasions, at least four days apart, a single oral (40 mg) or intravenous dose (20 mg) of famotidine, at 21.00 h in a randomised manner. Serial blood samples were collected and famotidine in plasma was determined by a HPLC/UV method. Plasma data were subjected to non compartmental pharmacokinetic analysis. There were no statistically significant differences in pharmacokinetic parameters between the two groups after either the intravenous or oral administration of famotidine. The findings suggest that the dose of famotidine may not require any adjustment in ascitic patients without renal failure.
Vinçon
G
G
Service de Pharmacologie Clinique, Hôpital Pellegrin, Université de Bordeaux II, France.
Baldit
C
C
Couzigou
P
P
Demotes-Mainard
F
F
Elouaer-Blanc
L
L
Bannwarth
B
B
Begaud
B
B
D000284:Administration, Oral; D000328:Adult; D001201:Ascites / Q000378:metabolism; D001682:Biological Availability; D015738:Famotidine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008104:Liver Cirrhosis, Alcoholic / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
D015738:Famotidine